R Yerushalmi1, B Dong2, J W Chapman2, P E Goss3, M N Pollak4, M J Burnell5, M N Levine6, V H C Bramwell7, K I Pritchard8, T J Whelan9, J N Ingle10, L E Shepherd2, W R Parulekar2, L Han2, K Ding2, K A Gelmon11. 1. Department of Medical Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva and Tel-Aviv University, Tel Aviv, Israel. 2. Canadian Cancer Trials Group (CCTG; Formerly, NCIC Clinical Trials Group), Queen's University, Kingston, Canada. 3. Massachusetts General Hospital Cancer Center, Boston, USA. 4. Department of Medical Oncology, Jewish General Hospital, McGill University, Montreal. 5. Department of Medical Oncology, Saint John Regional Hospital, Saint John. 6. Department of Oncology, McMaster University, Juravinski Cancer Center, Hamilton, Ontario. 7. Department of Medical Oncology, Tom Baker Cancer Centre, Alberta Health Services and University of Calgary, Calgary. 8. Department of Medical Oncology, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Canada. 9. Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, Ontario. 10. Department of Oncology, Mayo Clinic, Rochester, USA. 11. Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.
Abstract
BACKGROUND: We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy. METHODS: Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.27; and trastuzumab HERA/MA.24 were analyzed. The primary objective was to examine the effect of BMI change on breast cancer-free interval (BCFI) landmarked at 5 years; secondary objectives included BMI changes at 1 and 3 years; BMI changes on disease-specific survival (DSS) and overall survival (OS); and effects of baseline BMI. Stratified analyses included trial therapy and composite trial stratification factors. RESULTS: In pre-/peri-/early post-menopausal chemotherapy trials (N = 2793), baseline BMI did not impact any endpoint and increased BMI from baseline did not significantly affect BCFI (P = 0.85) after 5 years although it was associated with worse BCFI (P = 0.03) and DSS (P = 0.07) after 1 year. BMI increase by 3 and 5 years was associated with better DSS (P = 0.01; 0.01) and OS (P = 0.003; 0.05). In pre-menopausal endocrine therapy trial MA.12 (N = 672), patients with higher baseline BMI had worse BCFI (P = 0.02) after 1 year, worse DSS (P = 0.05; 0.004) after 1 and 5 years and worse OS (P = 0.01) after 5 years. Increased BMI did not impact BCFI (P = 0.90) after 5 years, although it was associated with worse BCFI (P = 0.01) after 1 year. In post-menopausal endocrine therapy trials MA.14 and MA.27 (N = 8236), baseline BMI did not significantly impact outcome for any endpoint. BMI change did not impact BCFI or DSS after 1 or 3 years, although a mean increased BMI of 0.3 was associated with better OS (P = 0.02) after 1 year. With the administration of trastuzumab (N = 1395) baseline BMI and BMI change did not significantly impact outcomes. CONCLUSIONS: Higher baseline BMI and BMI increases negatively affected outcomes only in pre-/peri-/early post-menopausal trial patients. Otherwise, BMI increases similar to those expected in healthy women either did not impact outcome or were associated with better outcomes. CLINICAL TRIALS NUMBERS: CAN-NCIC-MA5; National Cancer Institute (NCI)-V90-0027; MA.12-NCT00002542; MA.14-NCT00002864; MA.21-NCT00014222; HERA, NCT00045032;CAN-NCIC-MA24; MA-27-NCT00066573.
BACKGROUND: We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy. METHODS: Data from chemotherapy trials MA.5 and MA.21; endocrine therapy MA.12, MA.14 and MA.27; and trastuzumab HERA/MA.24 were analyzed. The primary objective was to examine the effect of BMI change on breast cancer-free interval (BCFI) landmarked at 5 years; secondary objectives included BMI changes at 1 and 3 years; BMI changes on disease-specific survival (DSS) and overall survival (OS); and effects of baseline BMI. Stratified analyses included trial therapy and composite trial stratification factors. RESULTS: In pre-/peri-/early post-menopausal chemotherapy trials (N = 2793), baseline BMI did not impact any endpoint and increased BMI from baseline did not significantly affect BCFI (P = 0.85) after 5 years although it was associated with worse BCFI (P = 0.03) and DSS (P = 0.07) after 1 year. BMI increase by 3 and 5 years was associated with better DSS (P = 0.01; 0.01) and OS (P = 0.003; 0.05). In pre-menopausal endocrine therapy trial MA.12 (N = 672), patients with higher baseline BMI had worse BCFI (P = 0.02) after 1 year, worse DSS (P = 0.05; 0.004) after 1 and 5 years and worse OS (P = 0.01) after 5 years. Increased BMI did not impact BCFI (P = 0.90) after 5 years, although it was associated with worse BCFI (P = 0.01) after 1 year. In post-menopausal endocrine therapy trials MA.14 and MA.27 (N = 8236), baseline BMI did not significantly impact outcome for any endpoint. BMI change did not impact BCFI or DSS after 1 or 3 years, although a mean increased BMI of 0.3 was associated with better OS (P = 0.02) after 1 year. With the administration of trastuzumab (N = 1395) baseline BMI and BMI change did not significantly impact outcomes. CONCLUSIONS: Higher baseline BMI and BMI increases negatively affected outcomes only in pre-/peri-/early post-menopausal trial patients. Otherwise, BMI increases similar to those expected in healthy women either did not impact outcome or were associated with better outcomes. CLINICAL TRIALS NUMBERS: CAN-NCIC-MA5; National Cancer Institute (NCI)-V90-0027; MA.12-NCT00002542; MA.14-NCT00002864; MA.21-NCT00014222; HERA, NCT00045032;CAN-NCIC-MA24; MA-27-NCT00066573.
Authors: Patrick T Bradshaw; Joseph G Ibrahim; June Stevens; Rebecca Cleveland; Page E Abrahamson; Jessie A Satia; Susan L Teitelbaum; Alfred I Neugut; Marilie D Gammon Journal: Epidemiology Date: 2012-03 Impact factor: 4.822
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Lawrence H Kushi; Colleen Doyle; Marji McCullough; Cheryl L Rock; Wendy Demark-Wahnefried; Elisa V Bandera; Susan Gapstur; Alpa V Patel; Kimberly Andrews; Ted Gansler Journal: CA Cancer J Clin Date: 2012 Jan-Feb Impact factor: 508.702
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: M N Levine; V H Bramwell; K I Pritchard; B D Norris; L E Shepherd; H Abu-Zahra; B Findlay; D Warr; D Bowman; J Myles; A Arnold; T Vandenberg; R MacKenzie; J Robert; J Ottaway; M Burnell; C K Williams; D Tu Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: Bette J Caan; Marilyn L Kwan; Georgina Hartzell; Adrienne Castillo; Martha L Slattery; Barbara Sternfeld; Erin Weltzien Journal: Cancer Causes Control Date: 2008-08-28 Impact factor: 2.506
Authors: Julia E Inglis; Michelle C Janelsins; Eva Culakova; Karen M Mustian; Po-Ju Lin; Ian R Kleckner; Luke J Peppone Journal: Support Care Cancer Date: 2019-07-02 Impact factor: 3.603
Authors: Dawn L Hershman; Cathee Till; Sherry Shen; Jason D Wright; Scott D Ramsey; William E Barlow; Joseph M Unger Journal: J Clin Oncol Date: 2018-03-27 Impact factor: 44.544
Authors: Natansh D Modi; Jin Quan Eugene Tan; Andrew Rowland; Bogda Koczwara; Ahmad Y Abuhelwa; Ganessan Kichenadasse; Ross A McKinnon; Michael D Wiese; Michael J Sorich; Ashley M Hopkins Journal: NPJ Breast Cancer Date: 2021-03-22